Q: Under the joint efforts of you and your team, Cancer World Congress has been successfully held 5 sessions since 2017. We also know that you, as the president, will host the 6th session in Portugal from 28 to 30 September 2022 (http://www.isidorolab.com/public/index.php/2104-2/2022-2/6th-cancer-world-congress-2022/). The topic "Personalized Cancer Diagnosis and Therapy" will also be featured. What motivates you to keep holding this meeting? By taking this opportunity, can you share and publicize this upcoming congress to our audiences?
Prof. Isidoro: This is a series of conferences on cancer that I started to coordinate in 2018, with the conference held in Bologna. In 2019 we held the conference in Prague, and that was the first in partnership with the JCMT for the publication of the proceedings. Due to COVID-19 we had to cancel the conference 2020 in Oslo, while the conference 2021 was held online. Now, we are happy to have the conference 2022 in person in Lisbon. I think there are some features that make this series of conference unique, attractive and very successful. First, it is not sponsored by any association nor by any industry, which means that it is open to all scientists with the only criteria of selection being the expertise in the field and the quality of the work to be presented. Second, at these conferences the participants always enjoy the lectures of prominent keynote and honorary speakers. Just to mention, in Prague 2018 we had the honorary lecture delivered by Thomas Seyfried, an expert in cancer cell metabolism. This year we will have Jacques Pouyssegur and Bonnie F Sloane as honorary speakers. Third, we have a session totally devoted to young investigators with awards for best communication. But the most attractive feature of our conferences is the friendly atmosphere that allows interactions between scientists, and especially helps young researchers to enter in contact with the experts and thus to have opportunities to grow and to perform their future studies in other laboratories abroad.
For video please click: https://jcmtjournal.com/images_2018/journals/jcmt_n2208185.mp4
Q: Based on this, JCMT is honored to partner with the Cancer World Congress to launch this Special Issue "Papers from the 6th Cancer World Congress 2022". What kind of articles do you plan to focus on through this Special Issue? Here you can share some information with our audience in advance to keep them looking forward to this issue.
Prof. Isidoro: We are very happy of this partnership that allows to publish the proceedings and full articles in the JCMT. I believe that our speakers, and especially the young researchers, will take this opportunity for publishing their most recent findings in the field. Altogether, we will have around 100 lectures and very likely many of these will turn into an original research paper or review article to be submitted to JCMT. With the assistance of the editorial staff, we will monitor the peer review process to secure a rapid decision and help to publish the best papers. Coherent with the theme of the conference, the papers will focus on the relevance of omics technologies for understanding cancer cell biology to improve early diagnosis and to design personalized therapy in cancer.
For video please click: https://jcmtjournal.com/images_2018/journals/jcmt_n2208186.mp4
Biography of the Interviewee
Prof. Ciro Isidoro, DSc, MD, an Associate Editor of the Journal of Cancer Metastasis and Treatment. He is full Professor of General Pathology and Immunology and of Experimental Oncology at the Università del Piemonte Orientale “A. Avogadro”, Novara, Italy, where he leads the Laboratory of Molecular Pathology at the Department of Health Sciences.
Prof. Isidoro is the founding member of International Society of Precision Cancer Medicine and of International Proteolysis Society, the Executive Vice President of International Association of Traditional and Complementary Medicine, and member of Italian Society of Cancerology, European Cancer Society, European Cell Biology Society, among others. Prof. Isidoro's research interests mainly focus on lysosomal proteolysis, pathogenesis of diseases, Cathepsin D, nanobioimaging, autophagy-lysosomal role in cancer.
For Full Interview Please Click: https://jcmtjournal.com/announcement/view/447